# Neurofibromatosis and Schwannoma Cases

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on Neurofibromatosis Type 1 and Type 2, genetic disorders characterized by the development of tumors in the nervous system. The research covers various aspects including the role of tumor suppressor genes, Schwann cell origin of neurofibromas, cognitive deficits associated with the condition, and the molecular mechanisms underlying the disease. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11173 |
| Works | 144 |

## Topic papers all

Showing 15 of 144.

- [Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis](https://scholariq.org/papers/sirolimus-for-angiomyolipoma-in-tuberous-sclerosis-complex-or/)
- [NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors](https://scholariq.org/papers/nccn-task-force-report-update-on-the-management-of-patients-with/)
- [Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma](https://scholariq.org/papers/radiation-plus-procarbazine-ccnu-and-vincristine-in-low-grade-glioma/)
- [Genomic Analysis of Non- <i>NF2</i> Meningiomas Reveals Mutations in <i>TRAF7</i> , <i>KLF4</i> , <i>AKT1</i> , and <i>SMO</i>](https://scholariq.org/papers/genomic-analysis-of-non-i-nf2-i-meningiomas-reveals-mutations-in-i-traf7-i-i/)
- [Neurofibromatosis type 1](https://scholariq.org/papers/neurofibromatosis-type-1/)
- [Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation](https://scholariq.org/papers/revised-diagnostic-criteria-for-neurofibromatosis-type-1-and-legius-syndrome-an/)
- [Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations](https://scholariq.org/papers/updated-international-tuberous-sclerosis-complex-diagnostic-criteria-and/)
- [The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis](https://scholariq.org/papers/the-membrane-cytoskeleton-linker-ezrin-is-necessary-for-osteosarcoma-metastasis/)
- [Selumetinib in Children with Inoperable Plexiform Neurofibromas](https://scholariq.org/papers/selumetinib-in-children-with-inoperable-plexiform-neurofibromas/)
- [Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas](https://scholariq.org/papers/activity-of-selumetinib-in-neurofibromatosis-type-1-related-plexiform/)
- [Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial](https://scholariq.org/papers/safety-pharmacokinetic-pharmacodynamic-and-efficacy-data-for-the-oral-mek/)
- [Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma](https://scholariq.org/papers/early-inactivation-of-p53-tumor-suppressor-gene-cooperating-with-nf1-loss/)
- [Evidence for Sequenced Molecular Evolution of <i>IDH1</i> Mutant Glioblastoma From a Distinct Cell of Origin](https://scholariq.org/papers/evidence-for-sequenced-molecular-evolution-of-i-idh1-i-mutant-glioblastoma-from/)
- [Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group](https://scholariq.org/papers/randomized-study-of-two-chemotherapy-regimens-for-treatment-of-low-grade-glioma/)
- [Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview](https://scholariq.org/papers/histopathologic-evaluation-of-atypical-neurofibromatous-tumors-and-their/)

## Topic primary papers

Showing 15 of 69.

- [Neurofibromatosis type 1](https://scholariq.org/papers/neurofibromatosis-type-1/)
- [Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation](https://scholariq.org/papers/revised-diagnostic-criteria-for-neurofibromatosis-type-1-and-legius-syndrome-an/)
- [The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis](https://scholariq.org/papers/the-membrane-cytoskeleton-linker-ezrin-is-necessary-for-osteosarcoma-metastasis/)
- [Selumetinib in Children with Inoperable Plexiform Neurofibromas](https://scholariq.org/papers/selumetinib-in-children-with-inoperable-plexiform-neurofibromas/)
- [Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas](https://scholariq.org/papers/activity-of-selumetinib-in-neurofibromatosis-type-1-related-plexiform/)
- [Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview](https://scholariq.org/papers/histopathologic-evaluation-of-atypical-neurofibromatous-tumors-and-their/)
- [Malignant Peripheral Nerve Sheath Tumors (MPNST): The Mayo Clinic Experience](https://scholariq.org/papers/malignant-peripheral-nerve-sheath-tumors-mpnst-the-mayo-clinic-experience/)
- [An Absence of Cutaneous Neurofibromas Associated with a 3-bp Inframe Deletion in Exon 17 of the NF1 Gene (c.2970-2972 delAAT): Evidence of a Clinically Significant NF1 Genotype-Phenotype Correlation](https://scholariq.org/papers/an-absence-of-cutaneous-neurofibromas-associated-with-a-3-bp-inframe-deletion-in/)
- [MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors](https://scholariq.org/papers/mek-inhibition-exhibits-efficacy-in-human-and-mouse-neurofibromatosis-tumors/)
- [Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1](https://scholariq.org/papers/assessment-of-benign-tumor-burden-by-whole-body-mri-in-patients-with/)
- [Imaging features of retroperitoneal and pelvic schwannomas](https://scholariq.org/papers/imaging-features-of-retroperitoneal-and-pelvic-schwannomas/)
- [ERK Inhibition Rescues Defects in Fate Specification of Nf1-Deficient Neural Progenitors and Brain Abnormalities](https://scholariq.org/papers/erk-inhibition-rescues-defects-in-fate-specification-of-nf1-deficient-neural/)
- [NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas](https://scholariq.org/papers/nf106-a-neurofibromatosis-clinical-trials-consortium-phase-ii-trial-of-the-mek/)
- [Management of neurofibromatosis type 1-associated plexiform neurofibromas](https://scholariq.org/papers/management-of-neurofibromatosis-type-1-associated-plexiform-neurofibromas/)
- [Genetic Causes of Brain Tumors: Neurofibromatosis, Tuberous Sclerosis, von Hippel-Lindau, and Other Syndromes](https://scholariq.org/papers/genetic-causes-of-brain-tumors-neurofibromatosis-tuberous-sclerosis-von-hippel/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.